UTR-MYCN

UTR-MYCN is an investigational RNA-based therapeutic developed by UTR Therapeutics for the treatment of MYCN-driven cancers. The drug utilizes a proprietary RNA rewriting platform that involves engineering destabilized AU-rich elements (ARE) into the 3' untranslated region (UTR) of the MYCN mRNA. This mechanism is designed to selectively destabilize the transcript, promoting its degradation and subsequently reducing the expression of the MYCN protein. MYCN is a transcription factor and a well-characterized oncogenic driver in several pediatric and adult malignancies. By downregulating MYCN, UTR-MYCN aims to inhibit tumor cell proliferation and survival. The program is currently in Phase 1 development for indications including rhabdomyosarcoma, neuroblastoma, and retinoblastoma.